Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...
Dr Mark Kris discusses the increasing precision of lung cancer therapies and the need for additional testing to find ...
Study Finds on MSN
Blood test accurately detects 81% of earliest lung cancers by looking for molecular chaos
In A Nutshell Johns Hopkins researchers developed a blood test that catches 81% of stage IA lung cancers (the earliest, most ...
Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations, ...
In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...
Yesterday, the U.S. Food and Drug Administration approved the first blood-based genetic test that can detect gene mutations in non-small cell lung cancer patients. The cobas EGFR Mutation Test v2 is a ...
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with ...
Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells to target tumors. TIL therapy, now FDA-approved for solid tumors, shows ...
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.
Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results